Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2013

View Archived Issues

Novel transgenic pig model of familial hypercholesterolemia

Vertex Pharmaceuticals synthesizes new protein kinase inhibitors

Argos Therapeutics enrolls first patients in phase III ADAPT study

Researchers at Amgen present novel TRPM8 antagonists

The Wisconsin Alumni Research Foundation patents novel vitamin D analogues

Celecoxib shows promise as adjunctive treatment in children with autism

AstraZeneca and Vanderbilt University enter collaboration

Galapagos delivers second candidate drug to Janssen Pharmaceutica

French grant awarded for development of epicutaneous pediatric RSV vaccine

Four NIH-supported studies focus on new treatments for Alzheimer's disease

CorMedix signs marketing agreement with MKM Co-Pharma for Neutrolin

Cytos updates on phase IIb allergic asthma study

Tysabri label update sought from the FDA and EMA

Detection of endometrial and ovarian cancers through DNA screening of Pap smears

European approval for Amyvid diagnostic radiopharmaceutical

FDA accepts for filing Tarceva sNDA

Unigene Laboratories designs polypeptides with anti-inflammatory activity

Isis Pharmaceuticals patents antisense modulators of FGFR-4

European approval for new 800-mg tablet of Prezista

Novel GnRH receptor antagonists emerge from Bayer R&D

New antidiabetic agents described in Metabolic Solutions Development patent

Zenobia Therapeutics develops novel LRRK2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...